Pharmacy Practice, Apex Institute of Pharmacy, Samaspur , Chunar , Mirzapur
One of the most popular over-the-counter treatments in the world is cough medication. This article assesses the potential therapeutic effects, safety profile, ingredient considerations, and regulatory dependability of the hypothetical Tregady 2025 cough syrup. We also examine the 2025 Madhya Pradesh cough syrup incident, which exposed systemic flaws in medication regulation and quality assurance in India and resulted in several child fatalities due to tainted syrups, to put its significance in actual healthcare settings
People frequently seek treatment from coughs, whether they are caused by viral infections, allergic reactions, or environmental factors. Cough syrups relieve symptoms, but their therapeutic value is inconsistent and frequently low. To gain the trust of both users and healthcare professionals, the hypothetical Tregady 2025 syrup would need to prove its efficacy and safety.
The Cough Syrup Tragedy of 2025 (also known as the Madhya Pradesh Poisoning Outbreak or the 2025 India Cough Syrup Crisis) is a terrible public health scandal that occurred in late 2025 when contaminated children's cough syrups killed at least 20–24 children in India, mostly under the age of five, mostly in the Chhindwara district of Madhya Pradesh, with additional cases in Rajasthan. Similar to previous international catastrophes associated with Indian-made syrups (e.g., Gambia 2022, Uzbekistan 2022–2023), this episode stands out as one of the most serious domestic examples of pharmaceutical contamination in recent Indian history. However, it happened solely within India and did not involve exports.
The Madhya Pradesh cough syrup crisis of 2025 is a sobering reminder that contamination or inadequate quality control can make a medication deadly, especially if it is sold without sufficient testing and supervision.
The general mechanism of cough syrups
Usually, cough syrups depend on one or more of the following:
Cough suppressants to reduce a cough reflex, such as dextromethorphan Demulcents (like honey or glycerin) to relieve sore throats; expectorants (like guaifenesin) to thin mucus
They do not treat illnesses like pneumonia or bronchitis; rather, their function is symptomatic alleviation. Additionally, the type of cough affects how effective they are: dry coughs may respond better to suppressants, while productive coughs may benefit more from expectorants.
Incident Details
Coldrif cough syrup (produced by Sresan Pharmaceuticals, based in Kancheepuram, Tamil Nadu; Batch No. SR-13, manufactured May 2025, expiring April 2027) was the main product implicated in the clusters of children (mostly under the age of five) in Madhya Pradesh's Chhindwara district (as well as nearby areas like Betul and Pandhurna) in late September to early October 2025). Extremely high quantities of diethylene glycol (DEG), a hazardous industrial solvent used in antifreeze and braking fluids, were confirmed by laboratory tests (Tamil Nadu and Madhya Pradesh drug labs) at roughly 46.28% to 48.6% w/v, hundreds of times above the allowable limit of 0.1%. A Tamil Nadu-based pharmaceutical company's Coldrif cough syrup was identified by local health officials as the cause of the spate of deaths. Diethylene glycol (DEG), an industrial solvent, was discovered to be dangerously high in laboratory tests, well above safe limits. When DEG is mistakenly used in place of pharmacopeial solvents, it is harmful to human organs and has previously resulted in widespread poisonings. Numerous children, the majority of whom were under five, had either passed away or been admitted to hospitals due to serious renal issues caused by the syrup by the middle of October 2025. DEG ontamination most likely stemmed from the adulteration or substitution of inexpensive industrial-grade substance for safe propylene glycol solvent, exposing supply-chain flaws (such as repackaging unopened containers from unlicensed vendors like Sunrise Biotech and Jinkushal Aroma).
Comprehending Diethylene Glycol (DEG): The Hazardous Substance Responsible for the Disaster:
Diethylene glycol (DEG) is a viscous, hygroscopic, colorless, odorless (or almost odorless), and somewhat pleasant liquid. Its chemical formula is (HOCH?CH?)?O — essentially a dimer of ethylene glycol connected by an ether bond. It is a byproduct of the production of ethylene glycol from ethylene oxide and is a member of the glycol family.
Legitimate Uses
DEG is widely used in industrial applications, including:
There is no acceptable application for DEG in pharmaceuticals or food items intended for human consumption. It is not a permitted excipient (solvent, diluent, or humectant) in medications like cough syrups; instead, safe substitutes like propylene glycol or pharmaceutical-grade glycerin (glycerol) are utilized.
Normal / Safe Range in Pharmaceuticals
Because of its toxicity, regulatory agencies rigorously restrict DEG as an impurity or contaminant in pharmaceutical excipients (such as glycerin and propylene glycol):
Permissible limit: According to USP-NF monographs (e.g., for glycerin, propylene glycol, sorbitol solution), DEG (and frequently ethylene glycol) in high-risk components cannot exceed (NMT) 0.1% (0.10%).
FDA guidelines for assessing high-risk medication components (2023).
WHO guidelines and warnings (for instance, levels in tainted cough syrup instances far beyond this, reaching up to 48.6% in recent incidents).
Up to 0.2% (U.S. rules) or 0.25% (Australia, even in toothpaste) in certain situations (e.g., as an impurity in polyethylene glycol for food additives).
In oral liquid medications, anything over 0.1% is regarded as hazardous and inferior.
In properly manufactured pharmaceuticals, DEG should be undetectable or well below 0.1% through rigorous testing of raw materials.
Unusual Range and Impact on the Human Body
DEG is quickly absorbed, circulated through the bloodstream, and primarily processed in the liver when consumed (primary route; limited cutaneous absorption unless on injured skin). According to animal toxicity studies (LD?¹ in rats: 2–25 g/kg), it is more dangerous for humans.
Important hazardous metabolite: Diglycolic acid (DGA) and 2-hydroxyethoxyacetic acid (HEAA) are the main culprits; unlike ethylene glycol, DEG does not create calcium oxalate crystals.
Poisoning occurs in three phases (often after repeated exposure in contaminated medicines):
Initial phase (0.5–12 hours post-ingestion): Gastrointestinal symptoms (nausea, vomiting, abdominal pain, diarrhea), inebriation-like effects (drowsiness, altered mental status), mild CNS depression, and developing metabolic acidosis.
Second phase (1–3 days): Severe anion-gap metabolic acidosis, acute kidney injury/failure (oliguria/anuria, elevated creatinine/BUN, cortical necrosis), liver toxicity, tachycardia, hypertension, hyperkalemia, and potential multi-organ failure leading to death without treatment.
Delayed phase (5–10+ days, if survived): Neurological complications — lethargy, facial paralysis, dysphonia, cranial nerve palsies, peripheral neuropathy, quadriplegia, coma, encephalopathy, and sometimes permanent disability or death.
Estimated doses:
• Toxic dose: As little as ~0.14–1 g/kg (or 14–174 mg/kg in certain outbreaks); the minimal toxic dose is unknown, however children are harmed by modest repeated exposures.
• Lethal dose: is roughly 1–1.63 g/kg (or ~1 mL/kg pure DEG); in children or those who receive treatment later, it is lower.
Untreated cases have a high death rate, particularly in youngsters; therapy includes hemodialysis, fomepizole/ethanol (to inhibit metabolism), supportive care, and acidosis correction.
This explains the catastrophic consequences of DEG contamination in cough syrups (like the 2025 India tragedy with about 46–48% DEG): safe solvent substitution with cheap industrial DEG causes rapid, preventable newborn deaths. Only use drugs from authorized vendors that have sufficient quality control.
Death Toll and Effects
• Although official accounts differ significantly by date, by mid-to-late October 2025, at least 20–26 children—mostly toddlers and infants—had died, and more had been admitted to hospitals due to kidney failure.
• Early counts: 6–9 deaths by early October, 17–19 by mid-October, and 24+ verified by October 15–20, 2025.Families reported purchasing the syrup over-the-counter or with a prescription for common colds and coughs; the majority of casualties came from rural and tribal regions in Chhindwara.
Quick Comparison Table: 2025 Tragedy vs. Prior Incidents
|
Location |
Primarily domestic (MP, Rajasthan) |
Exports to Africa/Central Asia |
|
Deaths |
20–24 children |
140+ children (across multiple countries) |
|
Toxin Level |
Up to ~48.6% DEG |
High DEG/EG, but lower concentrations |
|
Response |
Arrests, factory shutdown, WHO alert |
Export bans, WHO alerts, slower accountability |
|
Regulatory Lesson |
Domestic gaps despite export reforms |
Highlighted export testing needs |
Regulatory and Legal Response
Following preliminary testing, the Madhya Pradesh government outlawed Coldrif on October 2, 2025, extending the ban to all Sresan products.
On October 13, 2025, Tamil Nadu authorities sealed the factory, permanently shut down Sresan Pharmaceuticals, and suspended or revoked the company's manufacturing licenses.
On October 13, 2025, WHO released Medical Product Alert N°5/2025, cautioning the world against Coldrif, Respifresh TR (Rednex Pharmaceuticals), and ReLife (Shape Pharma) owing to DEG contamination; no evidence of exports was found, but surveillance was advised.
Other syrups (Respifresh TR and ReLife) were associated with fewer or no deaths, but they tested positive for DEG traces.
Criminal actions: Enforcement Directorate (ED) investigated money laundering and attached assets; manufacturer, doctor (such as Dr. Praveen Soni), medical representative, and others (including the doctor's wife) were arrested on charges of manslaughter, culpable homicide, and negligence; Sresan's owner, G. Ranganathan, was arrested.
Nationwide: CDSCO mandated risk-based inspections of more than 700 cough syrup producers; recalls were started; GMP compliance was tightened; and pediatric syrup recommendations were published.
Lessons for Products Like Tregady 2025
The MP incident demonstrates that, even for over-the-counter medications, chemical purity and regulatory vigilance are unavoidable:
Quality Assurance: Good Manufacturing Practices (GMP) and pharmacopoeial requirements for solvents and excipients must be followed by brands.
Transparent Labeling: Users and clinicians are reassured by clear information about ingredients and batch testing.
Pediatric Caution: Products must be thoroughly examined and dosed appropriately because children are especially vulnerable.
Regulatory Vigilance: To identify subpar or hazardous drugs early on, authorities require strong systems for continuous monitoring of marketed medications.
Key Lessons and Broader Implications
Why Preventable Cost-Cutting Kills: Routine medications became poison due to manufacturers' substitution of harmful DEG for financial reasons and the lack of batch testing. This highlights the necessity of routine, mandated screening of excipients at every level.
• The "regulatory gap" in DEG/EG testing for domestic-market medications allowed subpar items to reach vulnerable rural and tribal groups, while export limits tightened following scandals in 2022.
• Urgently Needed Systemic Reforms: Experts need better pharmacovigilance, supplier audits, digital traceability, real-time data sharing, unified drug safety authority, and limitations on over-the-counter pediatric cough syrups (many of which have no evidence in young children).
• responsibility and Trust: Even if criminal negligence charges are sought, complete chain responsibility is required; bereaved families should receive compensation, transparency, and assurances that lessons are used and not repeated Cycle.
Ultimately, this tragedy dispels myths about India's status as the "pharmacy of the world," serving as a reminder that low-priced generic drugs come at an intolerable human cost when quality is sacrificed. In order to ensure that no more children die from medications intended to treat illnesses, real improvement necessitates moving from reactive crisis management to proactive, strict protections. It is the shared duty of pharmacists, regulators, and legislators to restore confidence with steadfast dedication to safety.
CONCLUSION
The active components, safety profile, clinical support, and manufacturing standards of cough syrups should all be examined; nevertheless, Tregady 2025 cough syrup cannot be thoroughly analyzed without validated composition and clinical data. The Madhya Pradesh cough syrup tragedy in 2025 serves as a sobering warning that tainted or subpar cough medications can have disastrous effects, particularly on the most vulnerable.
When giving cough medications to young children in particular, consumers should exercise caution, give priority to reputable brands, and consult a doctor. To stop catastrophes in the future, healthcare providers and authorities must also maintain strict quality control.
REFERENCES
Dipendu Sahu*, Sunil Mistry, Shivi Singh, Abhay Singh, Shivani Maurya, Shreya Singh, Amit Kumar, Harshit Sharma, Vanshika Patel, Shraddha Patel, Deepak Maurya, Review of Tregady 2025 Cough Syrup: Safety, Effectiveness, and Important Takeaways from the Madhya Pradesh Cough Syrup Crisis, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 1, 1382-1387. https://doi.org/10.5281/zenodo.18298263
10.5281/zenodo.18298263
